Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc. (Nasdaq: ESLA) is a clinical-stage biopharmaceutical company focused on cancer immunotherapy that entered the public markets through a SPAC business combination. The company operates in the healthcare and life sciences sector, with its pipeline targeting oncology indications. An 8-K current report was filed with the SEC on August 1, 2023, under accession number 0001213900-23-061514, disclosing a material event following the company's SPAC transaction. ESLA reflects the continued use of blank-check vehicles as a path to public markets for early-stage biopharma companies seeking capital for clinical development programs. Sign up at SpacDesk for full filing history, transaction timelines, and real-time data on ESLA and hundreds of other SPAC-related companies.